

The Mixed Lymphocyte Reaction (MLR) results as described in Example 10, support this utility as this assay demonstrates that the Bolekine polypeptide stimulates the proliferation of T-lymphocytes. As shown in the table in Example 10, the Bolekine polypeptide, when added to T-cell culture in nanomolar amounts (12.40 nM and 124.00 nM respectively) significantly increases the proliferation of T-cells.

As described in the specification on page 2, lines 2-6, the chemokine MIP-2 (murine) is chemotactic for human neutrophils and induces local neutrophil infiltration when injected into the footpads of mice. The scientific hypothesis behind the cloning of Bolekine was that there may be a family of novel chemokines similar to MIP-2 with chemotaxis specifically for immune cells. As described in Example 11, Bolekine is shown to also have an immune cell specific chemoattractant property *in vivo*. The Skin Vascular Permeability assay determined that Bolekine can render the vasculature permeable and attract immune cells. Again, the increase in infiltration/migration of immune cells to an area would prove useful in fighting local infection.

The conclusion, as suggested by the specification, is that Bolekine would be useful in stimulating the cellular arm of the immune response to ward off infection. Applicants submit that the reduction of infection is a substantial, credible and "real world" utility as required by 35 U.S.C. § 101. Applicants respectfully request that this rejection be withdrawn.


In light of the above arguments, Applicants believe that this application is now in condition for immediate allowance and respectfully request that this case pass to issue. As no claim amendments have been made, Applicants have not included a formal listing of the current claims and their status, the Examiner is invited to contact the Applicants if this is in error.

The Examiner is invited to contact the undersigned at (650) 225-3733 if any issues may be resolved in that manner.

Serial No: 09/806,920
Filed: March 22, 2001

Respectfully submitted,
GENENTECH, INC.

By:



David A. Carpenter, Ph.D.

Reg. No. 45,945

July 2, 2003

1 DNA Way, MS 49
South San Francisco, CA 94080
Phone: (650) 225-3733
Fax: (650) 952-9881

09157



PATENT TRADEMARK OFFICE